RECRUITING

Risk Indicators of Sarcoidosis Evolution-Unified Protocol

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to develop prediction models that can prognosticate patients with sarcoidosis using clinical data and blood markers that can be obtained during a clinic visit.

Official Title

Development of Clinical Prediction Models for Pulmonary Outcomes in Sarcoidosis

Quick Facts

Study Start:2023-01-10
Study Completion:2026-03-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05567133

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:19 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Not specified
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Adults with a diagnosis of sarcoidosis over the age of 18
  2. 2. Case definition: we will follow the 1999 statement on sarcoidosis published by the American Thoracic Society for diagnosis which includes tissue biopsy confirmation and exclusion of alternative diagnoses including beryllium sensitization/chronic beryllium disease, mycobacterial, viral, and/or fungal infection
  1. 1. Inability to tolerate study procedures as determined by the investigator
  2. 2. Pregnant or breastfeeding
  3. 3. Concurrent medical diagnoses that would influence the expression of biomarkers will be considered an exclusion criterion. This includes diseases such as common variable immunodeficiency, HIV infection, or autoimmune diseases
  4. 4. Concurrent interstitial lung diseases such as hypersensitivity pneumonitis or idiopathic pulmonary fibrosis
  5. 5. Hematocrit (Packed Cell Volume) \< 25%

Contacts and Locations

Study Contact

Laura Koth
CONTACT
4155144369
laura.koth@ucsf.edu
Jessica Cardenas
CONTACT
jessica.cardenas@ucsf.edu

Principal Investigator

Laura Koth
PRINCIPAL_INVESTIGATOR
University of California, San Francisco

Study Locations (Sites)

University of Maryland
Baltimore, Maryland, 21201
United States
UT Southwestern
Dallas, Texas, 75390
United States

Collaborators and Investigators

Sponsor: University of California, San Francisco

  • Laura Koth, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-01-10
Study Completion Date2026-03-30

Study Record Updates

Study Start Date2023-01-10
Study Completion Date2026-03-30

Terms related to this study

Keywords Provided by Researchers

  • sarcoid, lung, immune

Additional Relevant MeSH Terms

  • Sarcoidosis, Pulmonary